Programme 16 January 2016
09.00 Registration with coffee & croissants
09.30 Welcome (Veerle Surmont, UGent)
09.35 Session 1: quality in lung cancer care
Chair: Annelies Janssens, UZA – Paul Baas, NKI Amsterdam, NL
09.35 Quality control and assessment in molecular pathology (Jo Van Dorpe, UGent)
10.00 Integrating outcome and toxicity in clinical benefit (Martijn Kerst, NKI, Amsterdam, NL)
10.25 Session 2: optimal treatment in stage I NSCLC
Chair: Yolande Lievens, UGent – Michèle De Waele, UZA
10.25 SAB Radiotherapy (Umberto Ricardi, Torino University, I)
10.45 VATS-resection (Rick Paul, VUmc, Amsterdam, NL)
11.05 Interactive vote (Thomas Malfait, UGent)
11.15 Coffee break
11.45 Session 3: controversies in thoracic oncology
Chair: Birgitta Hiddinga, UZA – Frank Vermassen, UGent
11.45 Immunotherapy: is more better? (Karim Vermaelen, UGent)
12.10 Anti-angiogenesis in mesothelioma: more than untargeted therapy? (Arnauld Scherpereel, CHRU Lille, F)
12.35 Surgery and mesothelioma: mythe or hype? (Harvey Pass, New York University, USA)
13.05 Summary (Jan van Meerbeeck, UAntwerpen)
13.10 Walking lunch
